News Related to Lung Adenocarcinoma

Cancer Immunotherapy Resistance Mechanisms Revealed Through Cellular Stress and Senescence Pathways

Apr 01, 2026

Research reveals therapy-induced senescent cancer cells and the integrated stress response pathway play dual roles in cancer immunotherapy resistance. The ATF4-LCN2 axis suppresses anti-tumor immunity by promoting immunosuppressive macrophages, while senescent cells can both enhance and inhibit immune responses. These findings highlight new targets for improving immunotherapy efficacy.

Cancer Survival Rates Reach 70% Milestone as Research Advances Continue

Mar 02, 2026

For the first time, 70% of cancer patients in the U.S. survive five years or more after diagnosis, according to the American Cancer Society's 2026 report. Advances in immunotherapy, CAR T-cell therapy, and screening technologies have driven significant improvements, particularly for lung cancer and myeloma. The definition of successful cancer care is evolving beyond survival to focus on quality of life and durable remissions.

KRAS Mutation Subtypes Show Distinct Immune Responses, Guiding Personalized Cancer Treatment

Mar 05, 2026

New research reveals that different KRAS mutation types create distinct tumor ecosystems with varying immune responses, potentially enabling personalized treatment strategies combining mutation-specific inhibitors with immunotherapy.

CAR-T Cell Advances Target Solid Tumors and Blood Cancers with New Strategies

Feb 27, 2026

Researchers develop ultra-sensitive CAR-T cells targeting CD70 for solid tumors and KRASG12V/HLA-A*02:01-specific CAR-T cells for cancers with KRAS mutations, demonstrating efficacy in preclinical models.

Study Validates Deuterium Modulation Effects on Cancer Gene Expression

Feb 14, 2026

A newly published study in Int. J. Mol. Sci. confirms that deuterium concentration directly influences gene expression in lung adenocarcinoma cells, validating HYD LLC's three-decade research on deuterium-depleted water as a complementary cancer therapy.